106results about How to "High therapeutic effect" patented technology

Oligonucleotides having a nucleotide sequence complementary to nucleotide numbers such as 2571-2607, 2578-2592, 2571-2592, 2573-2592, 2578-2596, 2578-2601 or 2575-2592 of the dystrophin cDNA (Gene Bank accession No. NM_004006.1) and therapeutic agents for muscular dystrophy comprising such oligonucleotides.

A self-emulsifying composition contains: 70 to 90% by weight of at least one compound selected from the group consisting of ω3 polyunsaturated fatty acids and their pharmaceutically acceptable salts and esters; 0.5 to 6% by weight of water; 1 to 29% by weight of a polyoxyethylene sorbitan fatty acid ester as an emulsifier (optionally including a polyoxyl castor oil, and not including lecithin); and lecithin in an amount of 3 to 40 parts by weight in relation to 100 parts by weight of ω3 polyunsaturated fatty acids and the like. The self-emulsifying composition is excellent in self-emulsifying property, composition dispersibility, emulsion stability, and absorbability, is free from ethanol and polyhydric alcohols or only has such an alcohol added thereto at a reduced concentration, and is useful for foods and pharmaceuticals.

A novel immunostimulatory oligonucleotide by which an IFN-inducing activity is enhanced and an inflammatory cytokine-inducing activity is reduced, and a pharmaceutical containing the same, and an application thereof are provided. That is, the present invention provides the immunostimulatory oligonucleotide composed of a base sequence represented by a formula: 5′-(G)MPXCGYQ(G)N-3′ (SEQ ID NO: 118) (X and Y are mutually independent and represent an arbitrary sequence which has a length of 0 to 10 nucleotides and does not contain 4 or more consecutive G residues, and a length of X+Y is 6 to 20 nucleotides; XCGY contains a palindrome sequence having a length of at least 8 nucleotides and has a length of 8 to 22 nucleotides; P and Q are mutually independent and represent one nucleotide other than G; M represents an integer of 6 to 10 and N represents an integer of 0 to 3) wherein a full length thereof is 16 to 37 nucleotides (except for an oligonucleotide composed of a base sequence represented by SEQ ID NO:5), the pharmaceutical application thereof.

Technical Field: TeaTechnical Problem: To provide a drinkable tea having a high therapeutic effect against atopic dermatitis.Means for Solving: It is characterized in that it contains extracts drawn from one, two or more medicinal herbs selected from the group consisting of Lightyellow Sophora Root, Isatis Leaf, and Terminalia Fruit. Atopic dermatitis can be cured by improving allergic constitution from the inside of body owing to antibacterial effect and antiviral effect of Lightyellow Sophora Root, Isatis Leaf and Terminalia Fruit, antiallergic effect of Lightyellow Sophora Root and Isatis Leaf, and intestinal mucosal protecting effect of Terminalia Fruit, or by a synergistic effect of them.In addition, the pharmacological effect in said extracts drawn from plants is enhanced, a pharmacological effects lacking in said extracts drawn from plants are added, or easiness of drinking the tea as a drinkable drug is improved and thus the therapeutic effect is improved by adding one, two or more auxiliary materials selected from the group of Japanese Angelica Root, Oldenlandia diffusa, Smilax Glarba, Dried Tangerine Peel, Wild Chrysanthemum Flower, Corydalis, Peppermint, Baikal Skullcap, Lithospermum, Kudingcha, Smartweed, and Licorice to the extracts drawn from plants.Principal Use: It is used for the therapy of dermatitis, particularly of atopic dermatitis.

A radiation irradiation device is provided that includes: a metal target that emits bremsstrahlung X-rays as a radiation beam due to irradiation with an electron beam; a radiation shielding member that includes a slit-shaped radiation passage portion and that is disposed downstream of the metal target in the radiation beam emission direction and is disposed such that a portion of the radiation beam passes through the radiation passage portion and the radiation beam incident to regions other than the radiation passage portion is blocked; and an electron beam generating device that irradiates, onto the metal target, an electron beam such that a diameter at a generation point of the emitted radiation beam is smaller than a length of an entry portion of the radiation passage portion along a length direction of the entry portion.

The invention relates a pharmaceutical composition containing botulinum toxin and a mucopolysaccharide uses thereof with increased pharmacological activity and long lasting botulinum toxin effect.

[Problems] To provide a novel use of multipotential stem cells originating in a fat tissue.[Means for Solving Problems] It is intended to provide a cell preparation which contains multipotential stem cells originating in a fat tissue and is usable for an ischemic disease, impairment of renal function, wound, urinary incontinence or osteoporosis. As the multipotential stem cells originating in a fat tissue, use is made of cells which proliferate in the case of centrifuging cells separated from a fat tissue and culturing the thus sedimented cells (an SVF fraction) under low-serum conditions. In an embodiment, a cell preparation containing the SVF fraction is provided.

TECHNICAL FIELD: Lotion for therapy of dermatitisTECHNICAL PROBLEM: To provide a lotion for therapy effective against atopic dermatitis.MEANS FOR SOLVING: It has a composition: Lightyellow Sophora Root, 3%; Turmeric, 2%; Magnolia Bark, 2%; Moutan Bark, 2%; Isatis Leaf, 1%; Borneo Camphor Tree (Dryobalanops aromatica Gaertn.f.), 1%; Amur Cork Tree, 2%; Angelicae Dahuricae Root, 1%; Lemon, 3%; Smartweed, 2%; Licorice, 0.5%; Cnidii Rhizoma, 0.5%; Japanese Angelica Root, 0.5%; salicylic acid, 0.5%; resorcinol, 0.5%; alcohol, 30%; and water, 48.5%.A significant therapeutic effect against atopic dermatitis is obtained by a synergistic effect between antibacterial, antiviral, antiallergic, antiphlogistic, and blood-circulation accelerating actions as pharmacological effects of Lightyellow Sophora Root, Turmeric, Magnolia Bark, Moutan Bark, Isatis Leaf, Borneo Camphor Tree (Dryobalanops aromatica Gaertn.f.), Amur Cork Tree, Angelicae Dahurikae Root, Lemon, Smartweed, and Licorice, accelerating action for skin permeation and antifungal-sterilizing action of Cnidii Rhizoma and Japanese Angelicae Root, accelerating action for keratinization and antifungal-sterilizing action of salicylic acid and resorcinol, as described above.Principal Use: It is used for the therapy of dermatitis, particularly of atopic dermatitis.

The present invention intended to provide an artificial polyclonal immunoglobulin composition having a high therapeutic effect and high safety, and being capable of stable supply in a large amount. Specifically provided is an artificial polyclonal immunoglobulin composition containing, as active ingredients, 204 polypeptides represented by amino acid sequences set forth in SEQ ID NOS: 1 to 204 of the sequence listing, the polypeptides being plural kinds of single chain variable fragments (also referred to as ScFvs) each comprised of a heavy chain variable region, heavy chain constant region 1, and hinge region (VH-CH1-hinge) of an immunoglobulin, in which the heavy chain variable regions are different each other.

The present invention is intended to provide an artificial polyclonal immunoglobulin composition or artificial immunoglobulin fragment composition having a high therapeutic effect and high safety, and being capable of stable supply in a large amount. Specifically provided is an artificial polyclonal immunoglobulin composition containing, as active ingredients, 204 polypeptides represented by amino acid sequences set forth in SEQ ID NOS: 1 to 204 of the sequence listing, the polypeptides being plural kinds of single chain variable fragments (also referred to as ScFvs) each comprised of a heavy chain variable region, heavy chain constant region 1, and hinge region (VH-CH1-hinge) of an immunoglobulin, in which the heavy chain variable regions are different each other. An artificial immunoglobulin fragment composition is also provided that can include at least one polypeptide comprising an amino acid sequence set forth in SEQ ID NOS: 1 to 204, for example, SEQ ID NO. 31.

This invention provides a therapeutic agent for arthrosis exerting inhibitory effects on articular cartilage destruction and high therapeutic effects on arthrosis. The invention provides a therapeutic agent for arthrosis which comprises, as an active ingredient, cyclic phosphatidic acid or carbacyclic phosphatidic acid.

This invention provides a therapeutic agent for arthrosis exerting inhibitory effects on articular cartilage destruction and high therapeutic effects on arthrosis. The invention provides a therapeutic agent for arthrosis which comprises, as an active ingredient, cyclic phosphatidic acid or carbacyclic phosphatidic acid.

Disclosed are chelating agent-conjugated α-MSH peptide derivatives, preparation methods thereof, and compositions for use in a diagnosis or treatment of a melanoma tumor containing the same as an active ingredient. The novel α-MSH peptide derivatives conjugated with chelating agent according to the present invention are highly selective to the melanocortin-1 receptor which is α-MSH receptor expressing in melanoma tumor and their labeling rate of a radioactive isotope is high. Also, they remain in kidney shortly and have high taking rate of the melanoma tumor. Therefore, with the aforesaid reasons, they may be effectively used for early diagnosis or treatment of melanoma tumor.

To provide a marker for determining sensitivity of a patient to an anti-cancer agent, which marker can determine whether or not the patient has a therapeutic response to the anti-cancer agent, and novel cancer therapeutic means employing the marker.The marker for determining the sensitivity of a subject to an anti-cancer agent including oxaliplatin or a salt thereof, fluorouracil or a salt thereof, and levofolinate or a salt thereof, the marker containing one or more genes selected from the group consisting of ALAD gene, C20orf43 gene, CABLES1 gene, CDC14B gene, GDA gene, HOXB6 gene, RPL7AP27 gene, TMEM18 gene, and UGT2B10 gene.